Skip to content
Clinical Development

[Webinar] Unveiling Tomorrow’s Cancer Solutions

  • February 29, 2024

Medpace CRO & TeleDaaS Discuss Advancements in Dosimetry

In an upcoming webinar, Medpace Radiation Oncologist, Jess Guarnaschelli, MD, and Dosimetry Specialist, Daphnée Villoing, PhD, are joined by Mirada Medical’s Chief Medical Officer, Mark Crockett, MD, and Chief Executive Officer, Jon DeVries, MBA, to discuss how cancer treatment is being transformed through redefined dosimetry. 

Save your spot today to learn more about the cutting-edge advancements in radiopharmaceuticals, dosimetry, and AI technologies.  Register now.

Expert Panelists:

Jess Guarnaschelli, MD
Senior Medical Director, Medpace

Daphnée Villoing, PhD
Dosimetry Specialist, Medpace

Mark Crockett, MD
Chief Medical Officer, Mirada Medical

Jon DeVries, MBA
Chief Executive Officer, Mirada Medical

A Deep Dive into Radiopharmaceuticals, Dosimetry, and AI Integration

Over the past 30 years, the risk of dying from cancer has consistently decreased, saving approximately 4 million lives in the United States. Despite this positive trend, 2024 is projected to mark a milestone with an estimated two million new cancer cases, presenting a new challenge.1 In the field of cancer treatment, the growing interest in radiopharmaceuticals and dosimetry is evident. The increasing demand for personalized medicine applications and their impact on clinical outcomes suggests a rising need for tailored dosage and treatment for each patient’s cancer profile. 

While the trajectory of radiopharmaceutical dosimetry is promising, current challenges persist within the clinical trial landscape. Deficiencies in existing guidelines from regulatory bodies such as the FDA, EANM, and FNIH, pose hurdles that need addressing. Despite these challenges, a recent survey reveals that many biopharmaceutical companies are actively incorporating dosimetry into their future development plans, highlighting a commitment to overcoming these challenges. 

The landscape is evolving with notable advancements in routine clinical dosimetry, driven by emerging technologies. These developments not only shift market dynamics and attract substantial funding but have broadened across various applications in radiation oncology. Looking ahead, the convergence of dosimetry and artificial intelligence (AI) presents a compelling frontier. AI-driven dosimetry methods hold the promise of delivering personalized, precision medicine. Positive insights from ongoing work suggest that AI has the potential to predict toxicity and outcomes, shaping a future where predicative dosimetry becomes a reality. 

Accelerating Global Radiation Therapy Clinical Development

Radiopharmaceutical drug development has advanced over the last decade, most notably in the field of imaging and oncology. Our in-house team of radiation oncologists and imaging experts understand the biological, clinical, regulatory, operational, and imaging considerations that must be factored in when designing and executing radiopharmaceutical trials. 

List of References

  1. American Cancer Society. Cancer Facts & Figures 2024. Atlanta: American Cancer Society; 2024. ↩︎